NCT04336241 2026-02-27Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsReplimune Inc.Phase 1 Active not recruiting36 enrolled
NCT03326258 2018-07-18Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 1/2 Withdrawn